Summaries & Associations of Study Results
TR-059 Estradiol mustard
Target Organs and Levels of Evidence
NTP Technical Report Number 059
Produced from Chemtrack Database 09/19/01
| CHEMICAL/ CAS NUMBER | PEER REVIEW DATE | PRIMARY USES | ROUTE/EXPOSURE LEVELS | STUDY LABORATORY |
|---|---|---|---|---|
| ESTRADIOL MUSTARD 22966-79-6 |
04/26/78 | ANTICANCER DRUG | Gavage R: 0,.62,1.25, M: 0,15,30 MG/KG/35 PER GROUP | Southern Research Institute |
| LEVELS OF EVIDENCE OF CARCINOGENICITY--ORGAN/TISSUE (NEOPLASM): | ||||
| MR: NEGATIVE | ||||
| FR: NEGATIVE | ||||
| MM: POSITIVE | LUNG (ALVEOLAR/BRONCHIOLAR ADENOMA, ALVEOLAR/BRONCHIOLAR CARCINOMA) | |||
| HEMATOPOIETIC SYSTEM (LYMPHOMA OR LEUKEMIA) | ||||
| HEART (SARCOMA) | ||||
| FORESTOMACH (SQUAMOUS CELL CARCINOMA) | ||||
| FM: POSITIVE | LUNG (ALVEOLAR/BRONCHIOLAR ADENOMA OR CARCINOMA) | |||
| HEMATOPOIETIC SYSTEM (LYMPHOMA) | ||||
| HEART (SARCOMA) | ||||
| FORESTOMACH (SQUAMOUS CELL CARCINOMA) | ||||
Web page last updated on February 10, 2006
